# ciloa.bio ## Posts - [Ciloa SAS in Japan - October 2025](https://ciloa.bio/ciloa-sas-in-japan-october-2025/) - [Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes](https://ciloa.bio/france-2030/): ‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only recombinant, stable and functional form of Adiponectin  First preclinical results confirm remarkable therapeutic potential in treatment of several metabolic diseases, in particular type 2 diabetes and obesity, affecting around two billion patients worldwide  Ciloa plans to use funding to implement biomanufacturing of candidate APN-sEV and demonstrate that innovative biotherapy meets all safety criteria to enter clinical phases I and IIa in treatment of obesity and type 2 diabetes Montpellier, France, July 7, […] - [Ciloa part of the French Delegation at BIO US 2025](https://ciloa.bio/bio-us-2025-2/): Ciloa is proud to be part of the French Delegation at BIOUS 2025 Let’s connect and share about our sEV bioengineering platform EVENGI and in progress applications of our lead candidate, APN-sEV.  Learn more about our breakthrough solution for obesity, diabetes, MASH and metabolic diseases based on adiponectin, a hormone known as the “Guardian Angel” for its anti-inflammatory, anti-oxidative stress, and insulin-sensitizing properties. BIO US 2025 Business France Healthcare - [Bio-Sourcing, Ciloa and Intract Pharma launch €3.4m EU project in inflammatory indications with €1.9M subsidies from Eureka Eurostars](https://ciloa.bio/bio-us-2025/): AB-BIOBETTER, led by Bio-Sourcing, to pioneer development of new oral formulation of adalimumab for inflammatory bowel diseases; offering patients less invasive, more cost-effective and potentially more potent treatment options Liège (Belgium), Montpellier (France) and London (UK), May 28, 2024 – Bio-Sourcing, with partners Ciloa and Intract Pharma, today announce the launch of a €3.4M ($3.7M) EU-funded program, including €1.9M in subsidies from EUREKA Eurostars. The three-year AB-BIOBETTER project aims to develop an oral antibody treatment for Inflammatory Bowel Diseases (IBD), such as Crohn’s disease and ulcerative colitis, as well as for other systemic immunology indications. Bio-Sourcing, a Belgian biotechnology company developing […] - [Ciloa secures €5 million for biomedicines and vaccines development](https://ciloa.bio/sed-volutpat-interdum-odio-id-pulvinar-leo-vulputate-et/): Ciloa secures €5 million for the development of its new generation of biomedicines and vaccines using exosomes The company finalized a €3.5 million fundraising and obtained €1.5 million in public funding as part of the “Emerging Infectious Diseases and CBRN Threats” call for proposals of the France 2030 investment plan, operated on behalf of the French government by Bpifrance. This aid was more specifically granted for the development of a natural vaccine against the Covid-19 delta variant.  With its own production unit to meet GMP (Good Manufacturing Practices) standards, Ciloa is now positioned as a major player in the development […] - [Ciloa selected in “Sanofi iTech Awards”](https://ciloa.bio/dapibus-venenatis-nisi/): Ciloa’s project among the 11 winners of the “Sanofi iTech Awards”  French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”. The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes. The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.   Montpellier, France, February 15, 2021 – Ciloa, a pioneer company specialized in the in vivo customization of exosomes, announced today the selection of its project as part of the “Sanofi iTech Awards” program. […] ## Pages - [Privacy Policy](https://ciloa.bio/privacy-policy/): Privacy Policy - [Cookie Policy](https://ciloa.bio/cookie-policy/): Cookie Policy - [sEV](https://ciloa.bio/sev/): sEVs Small extracellular vesicles (sEVs), the natural candidates for the next generations of biotherapeutics and vaccines Learn More Small extracellular vesicles (sEVS) Membrane proteins are essential actors in life, playing a key role in intercellular interactions. As such, they are the targets of most current and future therapies and hold themselves great therapeutic promise. However, their mastery is a challenge for the development of usable therapeutic tools. Over hundreds of millions of years, nature has evolved small extracellular vesicles (sEVs), which carry selected combinations of membrane proteins, as a complex tool for intercellular communication that can be propelled throughout the […] - [Technology](https://ciloa.bio/technology/): Unique sEV bioengineering technology Any type of protein, even the most complex ones, can be targeted to the sEV lumen or surface. Learn More A unique sEV bioengineering technology Ciloa has developed a unique patented technology of sEV bioengineering based on a Pilot Peptide (PP) that interacts with the ESCRT cellular machinery responsible sEV production. All types of proteins, even the most complex, can be sorted into the small extracellular vesicle (sEV) lumen or onto the sEV surface, where they are anchored in the membrane. In short, a chimeric DNA that encodes the protein of interest fused to the Pilot […] - [CVD](https://ciloa.bio/cvd/): APN-sEVs to protect against Cardiovascular diseases APN-sEVs, with of all their proven properties, show great promise as a treatment for cardiovascular diseases Learn More Overview Cardiovascular diseases (CVD) are a major cause of morbidity and mortality worldwide, representing the leading cause of death globally with over 17.9 million lives lost each year[1] ; by 2030, this number is expected to increase to >22.2 million. The vast majority of cardiovascular events are attributed to atherosclerosis, in which lipid plaques form in the vessel walls. CVD has been extensively associated with chronic low-grade inflammation[2] and involvement of both innate and adaptive immunity with […] - [MAFLD - MASH](https://ciloa.bio/mafld-mash/): MAFLD & MASH An out-of-the-box vision to treat metabolic-associated fatty liver disease (MAFLD) Learn More Overview Metabolic associated fatty liver disease (MAFLD) is closely linked to dietary caloric excess and a sedentary lifestyle. MAFLD is defined as hepatic steatosis (fat storage) associated with overweight or obesity, diabetes mellitus (T2DM), metabolic syndrome (high waist circumference, hypertension, hypertriglyceridemia, and low- high-density cholesterol). Cardiovascular disorders are the leading cause of mortality in patients with MAFLD, followed by extrahepatic malignancies. MAFLD is also associated with chronic kidney disease (CKD), polycystic ovarian syndrome (PCOS), obstructive sleep apnea (OSA), extrahepatic malignancies, osteoporosis, and cognitive disorders.[1] MAFLD […] - [Type 2 Diabetes](https://ciloa.bio/type-2-diabetes/): APN-sEV solution for Type 2 diabetes Adiponectin exposed on sEVs (APN-sEVs) promises to be the natural solution for combating Type 2 diabetes Learn More Overview Type 2 Diabete (T2D) currently affects 530 million people worldwide. T2D is a major risk factor for cardiovascular diseases (CVD) and MASLD causing the death of 1.5 million people per year in Europe with 67 million cases by 2030. The cellular and physiological mechanisms underlying the development of T2D are complex, involving pancreatic β-cell dysfunction, alterations in adipose tissue biology, and multi-organ insulin resistance. When hygienic-dietary solutions are not sufficient to improve health, most treatments […] - [Obesity](https://ciloa.bio/obesity/): A bio-therapeutic to tackle obesity Acting on pathways complementary to GLP-1, APN-sEVS are perfect GLP-1R co-agonists Learn More Overview Obesity (BMI > 30) is a complex, multifactorial pathology. It is not simply a matter of being overweight. This chronic disease is progressing at an alarming rate worldwide, with the number of cases doubling since 1990 among adults and quadrupling among adolescents, according to the WHO. Eating habits and a more sedentary lifestyle are major factors contributing to weight-related disorders by creating an energy imbalance between calories consumed and burned daily. Obesity represents a major risk factor for many common chronic […] - [Applications](https://ciloa.bio/applications/): Adiponectin sEV applications on metabolic diseases Stable, multimerised, native APN on sEVs for metabolic balance and health Learn More Natural messengers for innovative bio-therapeutics Using the EVENGI platform, Ciloa has succeeded in producing stable, multimerised, native adiponectin (APN) by targeting it to the surface of small extracellular vesicles (sEVs). Treatments using the resulting APN-sEVs have been shown to impact lipogenesis, gluconeogenesis and fatty acid oxidation. Such results can have dramatic implications on therapies of all metabolic diseases. Adiponectin signaling pathways From the scientific literature, it appears that adiponectin (APN) exerts its functional effects via two transmembrane receptors (AdipoR1 and AdipoR2) […] - [Vaccines](https://ciloa.bio/vaccines/) - [ApN sEVs](https://ciloa.bio/apn-sevs/): APN-sEVs, functional and stable adiponectin on sEVs Ciloa’s EV bioengineering platform, EVENGI, reproduces the natural functional form of adiponectin to fully exploit its wide therapeutic potential to improve patients’ health. Learn More Adiponectin (APN), a pleiotropic hormone Adiponectin is a molecule secreted by adipocytes (fat cells) that was discovered in 1995. Since its discovery, it has been the subject of over 27,000 scientific publications, highlighting its importance in the regulation of various metabolic processes and in the protection of cells from inflammation, oxidative-stress, and apoptosis. Adiponectin is a multi-faceted hormone with far-reaching effects on metabolic health, insulin sensitivity, fat metabolism, […] - [Pipeline](https://ciloa.bio/pipeline/): Pipeline Ciloa’s multi-purpose technology allows to develop a pipeline of therapeutic and preventive applications Learn More Therapeutic & Vaccine pipelines Our EVENGI sEV bioengineering and bioproduction platform is designed to help develop a new generation of biotherapeutics. The most advanced are those concerning metabolic diseases and also vaccines against emerging viruses. The next applications are in the oncology field for which sEV biotherapeutic candidates are in development. Therapeutic sEV Pipeline APN-sEV APN-sEV biotherapeutics Having overcome the challenge of producing stable and functional recombinant APN, Ciloa is now well-placed to develop APN-sEV drug candidates for several major diseases, with the first […] - [Platform](https://ciloa.bio/platform/): EVENGI Platform EVENGI harnesses both sEV bioengineering and sEV bioproduction to develop new generations of therapeutics and preventive solutions to improve patients’ lives. Learn More EVENGI: an advanced sEV platform Ciloa is an all-in-one R&D and biomanufacturing powerhouse, with complete sEV expertise based on over 24 years of experience. Our technology, R&D, know-how and cleanroom facilities have enabled us to create EVENGI a unique bioengineering and manufacturing platform for robust and reliable bioengineered sEV productions. This is evident in our pipeline of over 130 bioengineered small extracellular vesicles (sEVs) that are leading candidates for therapeutic and preventive applications. The company […] - [Science](https://ciloa.bio/science/): Science Customisation of sEVs for biotherapy treatments which are efficient in minute doses Learn More Overview on sEVs sEVs, sophisticated signal transducers sEVs are highly sophisticated means of information exchange developed by nature over hundreds of millions of years. They are extremely efficient due to: their minute size, which enables them to circulate throughout the body their ideal size and composition, which contribute to their physical stability their fluid lipid envelope, which allows molecules anchored to it to move around the presence of thousands of cell receptor ligand proteins the curvature of their membrane, which perfectly exposes these proteins and, […] - [Legal](https://ciloa.bio/legal/): Legal Disclaimer CIloa SAS is committed to keeping this website up to date and accurate. Should you nevertheless encounter anything that is incorrect or out of date, we would appreciate it if you could let us know. Please indicate where on the website you read the information. We will then look at this as soon as possible. Please send your response by email to: contact@ciloa.fr. We are not liable for loss as a result of inaccuracies or incompleteness, nor for loss resulting from problems caused by or inherent to the dissemination of information through the internet, such as disruptions or interruptions. […] - [Contact](https://ciloa.bio/contact/): Contact us for more information or for partnering Get in touch with us First Name* Last Name* Email * Category* GeneralAcademicBusiness developmentCareers Subject* Message* I agree to the use of my contact details to receive communications from Ciloa SAS Submit Contact Info Adress 356 rue Maurice Bejart, Montpellier 34080, France Phone +33 (0) 499 745 987 email contact@ciloa.fr - [About](https://ciloa.bio/about/): A new generation of sEV-based biotherapeutics that empower life Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of therapeutics and preventive solutions to improve patients’ lives. Learn More Mission and vision For hundreds of millions of years, nature has developed efficient biological solutions to control internal and external aggressions and to maintain a healthy physiological balance. One of its most advanced solutions is the small extracellular vesicles (sEVs, exosomes), which represent a very sophisticated communication system of the body. Ciloa’s mission is to harness the full potential of sEVs to develop new generations of […] - [News](https://ciloa.bio/news/): News May 28, 2024 Bio-Sourcing, Ciloa and Intract Pharma launch €3.4m EU project in inflammatory indications with €1.9M subsidies from Eureka Eurostars Read More March 8, 2022 Ciloa secures €5 million for biomedicines and vaccines development Read More February 5, 2021 Ciloa selected in “Sanofi iTech Awards” Read More 1 2 3 4 5 - [Home](https://ciloa.bio/): Harnessing natural messengers for innovative therapeutics Ciloa is a pioneer in the bioengineering of extracellular vesicles to develop new generations of therapeutics and preventive solutions to improve patients’ lives. Learn More Natural messengers for innovative bio-therapeutics The human body has developed extremely powerful and sophisticated tools for internal communication: small extracellular vesicles (sEVs, exosomes). sEVs are secreted by all types of cells and organs to communicate distantly with other organs and change their fate. sEVs can be thought as natural postal packages with an address made up of proteins and a message made up of proteins and RNA. Ciloa bioengineers […] [comment]: # (Generated by Hostinger Tools Plugin)